Management of Severe Pneumonia

Initial Antibiotic Therapy

The British Thoracic Society recommends administering parenteral antibiotics immediately after diagnosis to ensure prompt, high blood and lung concentrations of antibiotics 1
The preferred regimen is an IV combination of a broad-spectrum beta-lactamase stable antibiotic (co-amoxiclav, cefuroxime, or cefotaxime) and a macrolide (clarithromycin or erythromycin) 1, 2
This combination provides double coverage for likely pathogens in severe pneumonia and has been associated with better outcomes 4, 3

Streptococcus pneumoniae and Staphylococcus aureus remain predominant pathogens, but Gram-negative enteric bacilli, though uncommon, carry high mortality 4
Combination therapy offers coverage for both typical and atypical pathogens, particularly Legionella sp. 3, 6
Evidence indicates combination therapy is associated with better outcomes in severe pneumonia 4

Consider MRSA in patients hospitalized within the last few months 1
Adjust therapy if staphylococcal pneumonia is suspected or if not responding to empirical therapy 2
For nosocomial pneumonia caused by P. aeruginosa, add an aminoglycoside to the regimen 7

For severe microbiologically undefined pneumonia: 10 days of treatment 1
Extended treatment (14-21 days) is recommended when legionella, staphylococcal, or Gram-negative enteric bacilli pneumonia are suspected or confirmed 1, 2
Recent evidence suggests that biomarkers, particularly procalcitonin, may guide shorter treatment duration 7

Switch to oral therapy when clinical improvement is evident, temperature has been normal for 24 hours, and no contraindications to oral administration exist 1, 2, 4

If patient fails to improve, conduct a thorough review by an experienced clinician of clinical history and examination, prescription chart, and results of all available investigations 1, 2
Consider additional investigations, such as repeat chest radiograph, CRP and white cell count, and further specimens for microbiological testing 2

Delaying antibiotic administration beyond 4 hours after admission increases mortality 6
Failure to consider MRSA in recently hospitalized patients 1
Prolonged IV therapy when oral therapy would be appropriate 2